Literature DB >> 6848598

Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 S. pneumoniae without causing bacterial killing.

K Joiner, E Brown, C Hammer, K Warren, M Frank.   

Abstract

Gram-positive cocci resist direct killing by serum. The mechanism of resistance was studied by measuring consumption of terminal complement components from serum and uptake of purified, radiolabeled C7 and C9 on rough and encapsulated type 7 Streptococcus pneumoniae. Extensive consumption of C5, C7, and C9 occurred when 5 X 10(8) rough or type 7 pneumococci were incubated for 1 hr in 10% pooled normal human serum (PNHS). Approximately 10,000 molecules of C7 and C9 bound per organism during the same period of incubation. Twenty to 30% of C7 and C9 was released from rough organisms. Release was not due to autolysis since it occurred with glutaraldehyde-fixed organisms as well as in S. pneumoniae that were rendered resistant to autolysis by growth in ethanolamine. Between 10 and 30% of bound 125IC9 counts were eluted from the rough and type 7 organisms by incubation in 1 M NaCl or 0.01 M EDTA, which suggests that bound C5b-9 was not attached by predominantly ionic interactions. Elution of 44 to 74% of 125IC9 from live and glutaraldehyde-fixed organisms by 1% sodium deoxycholate suggests that hydrophobic bonds are involved in C5b-9 attachment. Trypsin cleaved 67 and 55% of 125IC9 counts from live rough and type 7 S. pneumoniae, respectively which indicates that the bound complex is not protected by the cell wall from proteolytic attack. Serum resistance in S. pneumoniae does not represent a failure to form C5b-9 on the bacterial cell wall but apparently reflects a failure of the bound complex to penetrate the thick peptidoglycan layer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation.

Authors:  Anna M Blom; Simone Bergmann; Marcus Fulde; Kristian Riesbeck; Vaibhav Agarwal
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

4.  Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  C J Parker; C M Soldato; W F Rosse
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

Review 5.  The complement system: 1983.

Authors:  J E Volanakis
Journal:  Surv Immunol Res       Date:  1984

Review 6.  The role of complement in host resistance to bacteria.

Authors:  E J Brown; K A Joiner; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1983

7.  Role of complement component C1q in phagocytosis of Listeria monocytogenes by murine macrophage-like cell lines.

Authors:  C Alvarez-Dominguez; E Carrasco-Marin; F Leyva-Cobian
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Activation of the classical and alternative pathways of complement by Treponema pallidum subsp. pallidum and Treponema vincentii.

Authors:  T J Fitzgerald
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

9.  Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense.

Authors:  D V Devine; R J Falk; A E Balber
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

10.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.